The Role of Olanzapine in the Treatment of Anorexia Nervosa
| Autor: | Dana DelDotto, Kaelen C Dunican |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Olanzapine
medicine.medical_specialty Anorexia Nervosa medicine.drug_class MEDLINE Atypical antipsychotic Anorexia PsycINFO Benzodiazepines 03 medical and health sciences 0302 clinical medicine medicine Humans Pharmacology (medical) 030212 general & internal medicine Psychiatry business.industry medicine.disease 030227 psychiatry Clinical trial Eating disorders Treatment Outcome Anorexia nervosa (differential diagnoses) medicine.symptom business medicine.drug |
| Zdroj: | Annals of Pharmacotherapy. 41:111-115 |
| ISSN: | 1542-6270 1060-0280 |
| Popis: | Objective: To evaluate the role of olanzapine in the treatment of anorexia nervosa. Data Sources: Literature was obtained through searches of MEDLINE (1966–December 2006), EMBASE (1980–4th Quarter 2006), and PsycINFO (1985–December 2006) and a bibliographic review of published articles. Key terms used in the searches included anorexia nervosa, antipsychotics, eating disorders, olanzapine, and Zyprexa. Study Selection And Data Extraction: All English language articles that were identified from the search were evaluated. All primary literature was included in the review. Data Synthesis: In several case reports and most clinical trials, patients with anorexia nervosa successfully gained weight while being treated with olanzapine. Moreover, many patients treated with olanzapine achieved a healthy body weight. Case reports and trials identified additional benefits of olanzapine, including reduction in delusional thinking; improvement in body image, sleep, depressive symptoms, adherence to treatment, and eating-disorder symptoms; and decreased agitation and premeal anxiety. Conclusions: Preliminary evidence supports the use of olanzapine for treatment of anorexia nervosa by demonstrating that olanzapine 2.5–15 mg daily promotes weight gain and has positive effects on associated psychological symptoms. Limitations of the reported data include small sample size, low completion rate in clinical trials, and open-label trial design. Although olanzapine appears to have a potential role in the treatment of anorexia nervosa that has been unresponsive to other therapy, randomized, placebo-controlled studies with larger sample sizes are necessary to establish its role in therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|